Anda di halaman 1dari 16

Claris Injectables

Vision & Mission

VISION

To be one of the world's leading and most


admired pharmaceutical companies in the
global generics industry.

To continually create value and bring pride MISSION


to our stakeholders, partners, customers, A world-class organisation, built on,
and the community at large. Outstanding performance led by
To preserve Earth's most precious resource... Entrepreneurial culture
Human Lives Product quality through
Emotional Pharmacopoeia
Management capability, efficient
processes and technology
Youth, hard work, and discipline

Achieved in a manner of fairness,


honesty, and corporate responsibility.
2
Business Landscape

Claris Presence

Integrated
Development, Life Saving Regulated Discovery Led/
Injectables
Manufacturing, Patented Brand & Support NDDS Markets Inventive
Marketing,
Supply

Contract Authourised
Development and Critical Care Semi-regulated/
and/or Formulations Inhalational & Developmental/
Branded & Orals Emerging Markets Innovative
Manufacturing Generic Support

Primary Generic
Outsourcing/ Un-regulated
Generic Healthcare APIs Ointments Product
Marketing/ Markets
& Formulation
Supply
OTC

Business Product Therapy & Drug Formulation Delivery Markets R&D

3
Quick Facts

Wholly-owned subsidiary of Claris Lifesciences Limited - collectively Claris -


dealing in Specialty Injectables business

Presence in 100+ countries, including Regulated Markets

60+ products across therapies including anesthesia & analgesics, blood products,
anti-infectives, critical care, and nephrology

About 900 registrations worldwide, with 300 under approval

Key regulatory approvals: US FDA, MHRA (UK), TGA (Australia), GCC FDCA

Delivery systems: bags (PVC & NPVC), vials, ampoules, glass bottles

Key technological capabilities: emulsion and aqueous

Manpower: 1,300+
All figures as on Dec 31, 2016 4
Global Footprint and Network

Market presence across


100+ countries worldwide

Established Sales &


Marketing and
Distribution Network
across India, other Emerging
Markets, and Regulated Markets

Robust network enables reach


to a large number of
customers - doctors, medical
professionals, and hospitals.

Regulated + Far East Africa Asia

Latam MEGNA CIS


Figure as on Dec 31, 2016 5
Regulatory Capabilities

About 900 registrations worldwide, with 300 under approval

In-house regulatory teams

Sustainable compliance policy for Pharmacovigilance

Key Regulatory Approvals:

US FDA, USA MHRA, UK TGA, Australia GCC FDCA

All figures as on Dec 31, 2016 6


Manufacturing Capabilities

Manufacturing & Quality awards like IDMA and Frost & Sullivan IMEA

Manufacturing Technologies
o Large volume parenterals in glass bottles
o Emulsion manufacturing
o Bag manufacturing (PVC & Non-PVC)

Key International Suppliers


o Double-pass Reverse Osmosis System - Christ (Switzerland)
o Distillation Columns - Stilmas (Italy)
o Manufacturing Vessels - Diesel (Germany)

7
Developmental Capabilities

R&D facilities approved by Department of Science & Technology, Govt. of India

8
Key Products

Anesthesia & Analgesia Blood Products Anti-infectives

Propofol (1% & 2%) Heparin Sodium Ciprofloxacin

Propofol MCT LCT Fluconazole

Paracetamol IV Linezolid

Bupivacaine Moxifloxacin

Midazolam
Lidocaine

9
9
Key Products (contd.)

Plasma Volume
Renal & Transplant Other Injectables
Expanders

Tetrastarch Iron Sucrose Ondansetron


Erythropoietin Dobutamine
Alpha Ketoanalogue Furosemide
Metoprolol
Norepinephrine - Only for the USA

10
10
Key Innovations

Propofol

Very few manufacturers of Propofol across the world


Claris Propofol - registered in over 80 countries
including Europe, Australia, and other Regulated Markets
Most stable Propofol formulation in globally
Best in class in maintenance, TIVA, and for ICU/MAC sedation

Propofol MCT-LCT
o An advanced technology ensuring less pain
o Even suitable for children under 3 months

11
Key Innovations (contd.)

Iron Sucrose

Bio-equivalent with the innovator

Claris has developed it's own API

Registered in over 30 countries

Building an injectables iron portfolio

12
Key Innovations (contd.)

Anti-infectives

Large product basket including advance anti-infectives


Products available across all delivery systems, i.e., glass bottles, non-PVC/PVC bags
Large manufacturing capacities

Paracetamol IV

Claris is the first in India to launch the product in non-PVC


bags which provides added protection from light & moisture.
Can be administered by intravenous route to treat
short-term moderate pain and fever.

13
Branding & Promotion

Claris uses variety of branding & promotional tools to reinforce visibility in the market.
Indoor Branding Tools
o Creative promotional campaigns
o Plant visits by delegates
o Product launch campaigns
o Scientific literature
o Product brochures & leaflets

Outdoor Branding Tools


o Audio-Visual Presentations (AVPs)
o Conference participation
o Continuous Medical Education (CMEs)

Our initiatives help us


o Gain insights on competitors activities & stay
abreast with latest developments in industry
o Reach out to key customers & business associates
o Indulge in scientific interactions with the medical fraternity
14
Organisational Profile

Young & fast growing organisation


Belief in People Power
Value-driven, fair, and transparent culture
Effective rewards and recognition program
Developmental framework includes
o Internal trainings based on competency mapping
o External trainings at prestigious institutions

15
Way Ahead

We are committed to continuously


scale-up our efforts and resources in
bringing innovative & affordable medical
care products to patients worldwide,
thereby contributing to the well-being of
Earths most precious resource

Human Lives

16